Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001

Laboratory Investigation

Volumn 92, Issue 10, 2012, Pages 1503-1514

  Lan, Rongfeng ^a   Lin, Guimiao ^a   Yin, Feng ^a   Xu, Jun ^a   Zhang, Xiaoming ^a   Wang, Jing ^a   Wang, Yanchao ^a   Gong, Jianxian ^a   Ding, Yuan Hua ^b   Yang, Zhen ^a   Lu, Fei ^a   Zhang, Hui ^a,c,d  

^a PEKING UNIVERSITY   (China)

^b PFIZER INC   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

Aurora kinase; CBB2001; geminin; mitosis; Plk1 kinase

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA KINASE INHIBITOR; CBB 2001; CYCLIN B1; GEMININ; POLO LIKE KINASE 1; RIGOSERTIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MITOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH;

EID: 84866840285     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.114     Document Type: Article

References (41)

1. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330.
2. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-440.
3. Eckerdt F, Strebhardt K. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 2006;66:6895-6898.
4. Moshe Y, Boulaire J, Pagano M, et al. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci USA 2004;101: 7937-7942.
5. Nakajima H, Toyoshima-Morimoto F, Taniguchi E, et al. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 2003;278:25277-25280.
6. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002; 3:341-348.
7. Golsteyn RM, Mundt KE, Fry AM, et al. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995;129:1617-1628.
8. Oshimori N, Ohsugi M, Yamamoto T. The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity. Nat Cell Biol 2006;8:1095-1101.
9. Baumann C, Korner R, Hofmann K, et al. PICH a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell 2007;128:101-114.
10. Pouwels J, Kukkonen AM, Lan W, et al. Shugoshin 1 plays a central role in kinetochore assembly and is required for kinetochore targeting of Plk1. Cell Cycle 2007;6:1579-1585.
11. Kurasawa Y, Yu-Lee LY. PICH and cotargeted Plk1 coordinately maintain prometaphase chromosome arm architecture. Mol Biol Cell 2010;21:1188-1199.
12. Wu ZQ, Liu X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci USA 2008;105:1919-1924.
13. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148-152.
14. Yamamoto Y, Matsuyama H, Kawauchi S, et al. Overexpression of pololike kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006;70:231-237.
15. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-570.
16. Kanaji S, Saito H, Tsujitani S, et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006;70:126-133.
17. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002;99:8672-8676.
18. Guan R, Tapang P, Leverson JD, et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-2704.
19. Macurek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008;455:119-123.
20. Seki A, Coppinger JA, Jang CY, et al. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008;320:1655-1658.
21. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-936.
22. Taylor S, Peters JM. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 2008;20:77-84.
23. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53 cells. EMBO J 2002;21:483-492.
24. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065.
25. Lu F, Lan R, Zhang H, et al. Geminin is partially localized to the centrosome and plays a role in proper centrosome duplication. Biol Cell 2009;101:273-285.
26. Cooper S, Iyer G, Tarquini M, et al. Nocodazole does not synchronize cells: implications for cell-cycle control and whole-culture synchronization. Cell Tissue Res 2006;324:237-242.
27. Emmitte KA, Adjabeng GM, Andrews CW, et al. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett 2009;19: 1694-1697.
28. Higa LA, Banks D, Wu M, et al. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 2006;5:1675-1680.
29. Higa LA, Mihaylov IS, Banks DP, et al. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 2003;5:1008-1015.
30. Higa LA, Wu M, Ye T, et al. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol 2006;8:1277-1283.
31. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-5794.
32. Chen Q, Zhang X, Jiang Q, et al. Cyclin B1 is localized to unattached kinetochores and contributes to efficient microtubule attachment and proper chromosome alignment during mitosis. Cell Res 2008;18: 268-280.
33. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315.
34. Johnson EF, Stewart KD, Woods KW, et al. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 2007;46:9551-9563.
35. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007;2:247-250.
36. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-461.
37. Kothe M, Kohls D, Low S, et al. Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 2007;46:5960-5971.
38. Zhong H, Xin S, Zhao Y, et al. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish. Mol Biosyst, 6:1463-1468.
39. Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009;16:876-882.
40. Bashir T, Dorrello NV, Amador V, et al. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004;428:190-193.
41. Wei W, Ayad NG, Wan Y, et al. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004;428:194-198.